ClinicalTrials.Veeva

Menu

Study of Predictive Factors of Chemoresistance in Ovarian Cancer (FaCliBioCCo)

R

Rennes University Hospital

Status

Completed

Conditions

Ovarian Cancer

Treatments

Procedure: Cancer treatment

Study type

Observational

Funder types

Other

Identifiers

NCT02878122
35RC15_3007_FaCliBioCCo

Details and patient eligibility

About

Epithelial ovarian cancer (EOC) has a poor prognosis. EOC management requires debulking surgery and chemotherapy based on taxol and carboplatine. Initial response is often good, but most often a recurrence occurred in the first 18 months. Early recurrence signs chemoresistance and palliative treatment. The study of predictive clinical or biological factors is required to adapt therapeutic and develop new treatments.

Enrollment

13 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patient > 18 years of age
  • patient with histological proven epithelial ovarian cancer

Exclusion criteria

  • patients who can not give their own consent
  • patients without ovarian cancer

Trial design

13 participants in 1 patient group

Patients with epithelial ovarian cancer
Description:
Cancer treatment
Treatment:
Procedure: Cancer treatment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems